@article{42a28034420a47d79f0d4ce01c371d61,
title = "Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland",
abstract = "Limited therapeutic options have highlighted the demand for new treatment modalities for patients with advanced neuroendocrine tumors (NET). Promising results of initial studies have warranted the implementation of peptide receptor radionuclide therapy (PRRT) in clinical practice. However, this treatment option still needs clinical evaluation.",
keywords = "Adult, Aged, Cohort Studies, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Radiopharmaceuticals, Receptors, Peptide, Retrospective Studies, Switzerland, Treatment Outcome",
author = "Pfeifer, {Andreas Klaus} and Tine Gregersen and Henning Gr{\o}nb{\ae}k and Hansen, {Carsten Paln{\ae}s} and Jan M{\"u}ller-Brand and {Herskind Bruun}, Karin and Klaus Krogh and Andreas Kj{\ae}r and Ulrich Knigge",
note = "Copyright {\textcopyright} 2011 S. Karger AG, Basel.",
year = "2011",
doi = "10.1159/000324096",
language = "English",
volume = "93",
pages = "189--96",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S./Karger AG",
number = "3",
}